These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2850903)

  • 1. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G; Salanitri G; Catania G
    Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients.
    Palareti G; Legnani C; Bianchini B; Guazzaloca G; Maccaferri M; Marabini A; De Iaco P; Marcozzi S; Mancini L; Orlandi C
    Int Angiol; 1989; 8(1):47-52. PubMed ID: 2768958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY; Hawthorne WJ; Coombs R; Fletcher JP
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
    Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
    Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
    Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis.
    Carelli G; Maffei FH; Mattar L; Ferrari IC; Thomazini-Santos IA; de Carvalho LR
    Pathophysiol Haemost Thromb; 2005; 34(6):263-8. PubMed ID: 16772737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low molecular weight heparin on coagulation parameters and bleeding time in healthy volunteers.
    Warning A; Nies D; Wolf H; Welzel D
    Arzneimittelforschung; 1987 Jul; 37(7):847-9. PubMed ID: 2823841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery.
    Speziale F; Verardi S; Taurino M; Nicolini G; Rizzo L; Fiorani P; Palazzini E
    Pharmatherapeutica; 1988; 5(4):261-8. PubMed ID: 3174726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).
    Dettori AG; Tagliaferri A; Dall'Aglio E; Pini M
    Int Angiol; 1988; 7(3 Suppl):7-18. PubMed ID: 2850327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.